NASDAQ:PROF

Profound Medical Stock Forecast, Price & News

$18.74
-1.32 (-6.58 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.66
Now: $18.74
$20.09
50-Day Range
$18.63
MA: $21.18
$23.42
52-Week Range
$11.06
Now: $18.74
$28.97
Volume47,775 shs
Average Volume82,728 shs
Market Capitalization$380.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Profound Medical logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PROF
CUSIPN/A
CIKN/A
Phone647 476 1350
Employees109
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.17 million
Book Value$0.92 per share

Profitability

Net Income$-15,220,000.00
Net Margins-275.12%

Miscellaneous

Market Cap$380.23 million
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Here's what to expect from Profound Medical's earnings report
February 28, 2021 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

361st out of 2,018 stocks

Surgical & Medical Instruments Industry

33rd out of 169 stocks

Analyst Opinion: 3.6Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$18.74
-1.32 (-6.58 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PROF News and Ratings via Email

Sign-up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Profound Medical (NASDAQ:PROF) Frequently Asked Questions

Is Profound Medical a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Profound Medical in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Profound Medical stock.
View analyst ratings for Profound Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Profound Medical?

Wall Street analysts have given Profound Medical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Profound Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Profound Medical?

Profound Medical saw a increase in short interest in March. As of March 15th, there was short interest totaling 447,600 shares, an increase of 36.8% from the February 28th total of 327,100 shares. Based on an average trading volume of 90,900 shares, the short-interest ratio is currently 4.9 days. Approximately 2.5% of the company's stock are short sold.
View Profound Medical's Short Interest
.

When is Profound Medical's next earnings date?

Profound Medical is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Profound Medical
.

How were Profound Medical's earnings last quarter?

Profound Medical Corp. (NASDAQ:PROF) issued its quarterly earnings results on Tuesday, March, 2nd. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.11. The firm had revenue of $2.88 million for the quarter, compared to the consensus estimate of $3.03 million. Profound Medical had a negative net margin of 275.12% and a negative trailing twelve-month return on equity of 33.69%.
View Profound Medical's earnings history
.

How has Profound Medical's stock been impacted by COVID-19 (Coronavirus)?

Profound Medical's stock was trading at $10.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PROF shares have increased by 70.5% and is now trading at $18.74.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PROF?

5 analysts have issued 1 year target prices for Profound Medical's shares. Their forecasts range from $28.25 to $34.00. On average, they expect Profound Medical's stock price to reach $31.42 in the next year. This suggests a possible upside of 67.6% from the stock's current price.
View analysts' price targets for Profound Medical
or view top-rated stocks among Wall Street analysts.

Who are Profound Medical's key executives?

Profound Medical's management team includes the following people:
  • Dr. Arun Swarup Menawat, Chairman & CEO (Age 66, Pay $539.06k)
  • Mr. Aaron Davidson M.B.A., MBA, CFO & Sr. VP of Corp. Devel. (Age 53, Pay $183.4k)
  • Dr. Mathieu Burtnyk, Vice-Pres of Clinical Affairs
  • Mr. Stephen Kilmer, Investor Relations
  • Mr. Jacques F. Cornet, VP of Marketing & Bus. Devel. (Age 65)
  • Mr. Michael Mydra, VP & Head of Global Market Access

Who are some of Profound Medical's key competitors?

What is Profound Medical's stock symbol?

Profound Medical trades on the NASDAQ under the ticker symbol "PROF."

How do I buy shares of Profound Medical?

Shares of PROF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Profound Medical's stock price today?

One share of PROF stock can currently be purchased for approximately $18.74.

How much money does Profound Medical make?

Profound Medical has a market capitalization of $380.23 million and generates $4.17 million in revenue each year. The company earns $-15,220,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

How many employees does Profound Medical have?

Profound Medical employs 109 workers across the globe.

What is Profound Medical's official website?

The official website for Profound Medical is www.profoundmedical.com.

Where are Profound Medical's headquarters?

Profound Medical is headquartered at 2400 SKYMARK AVENUE UNIT 6, MISSISSAUGA A6, L4W 5K5.

How can I contact Profound Medical?

Profound Medical's mailing address is 2400 SKYMARK AVENUE UNIT 6, MISSISSAUGA A6, L4W 5K5. The company can be reached via phone at 647 476 1350 or via email at [email protected]


This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.